Evidence map›Paper›PMID 34685670›Full record

ArticleCells2021

Myricetin 3-

Fatih Karadeniz, Jung Hwan Oh, Hyun Jin Jo, Youngwan Seo, Chang-Suk Kong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Therapeutic potential ofFrontiers in pharmacology · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Hyunganol II Exerts Antiadipogenic Properties via MAPK-Mediated Suppression of PPAREvidence-based complementary and alternative medicine : eCAM · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fatih KaradenizMarine Biotechnology Center for Pharmaceuticals and Foods, College of Medical and Life Sciences, Silla University, Busan 46958, Korea.
Jung Hwan OhMarine Biotechnology Center for Pharmaceuticals and Foods, College of Medical and Life Sciences, Silla University, Busan 46958, Korea.
Hyun Jin JoDepartment of Food and Nutrition, College of Medical and Life Sciences, Silla University, Busan 46958, Korea.
Youngwan SeoDivision of Marine Bioscience, Korea Maritime and Ocean University, Busan 49112, Korea.
Chang-Suk KongMarine Biotechnology Center for Pharmaceuticals and Foods, College of Medical and Life Sciences, Silla University, Busan 46958, Korea.ORCID 0000-0002-2304-9304
Silla University · KRKorea Maritime and Ocean University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural bioactive substances are promising lead compounds with beneficial effects on various health problems including osteoporosis. In this context, the goal of this study was to investigate the effect of myricetin 3-

Indexed as

AdipogenesisOsteogenesisAdipocytesAlkaline PhosphataseBiomarkersBone Morphogenetic ProteinsCalcification, PhysiologicCell DifferentiationCell ProliferationFlavonoidsGene Expression RegulationHumansLipid MetabolismMAP Kinase Signaling SystemMesenchymal Stem CellsOsteoblastsAlkaline PhosphataseBiomarkersBone Morphogenetic ProteinsFlavonoidsmyricetinadipogenesisMSCmyricetin 3-O-β-D-galactopyranosideosteoblastogenesisWnt/BMP

Identifiers

PMID34685670
PMCPMC8534343
OpenAlexW3207193661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.